

# Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

## CD279 (PD1) Antibody, anti-human, PE

RRID:AB\_2727929

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-117-384, RRID:AB\_2727929

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2727929](http://antibodyregistry.org/AB_2727929)

**Proper Citation:** Miltenyi Biotec Cat# 130-117-384, RRID:AB\_2727929

**Target Antigen:** CD279 (PD1)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-096-164. (RRID:AB\_10828693).

**Antibody Name:** CD279 (PD1) Antibody, anti-human, PE

**Description:** This monoclonal targets CD279 (PD1)

**Target Organism:** human

**Clone ID:** clone PD1.3.1.3

**Antibody ID:** AB\_2727929

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-117-384

**Record Creation Time:** 20250820T012335+0000

**Record Last Update:** 20250820T104850+0000

### Ratings and Alerts

No rating or validation information has been found for CD279 (PD1) Antibody, anti-human, PE.

No alerts have been found for CD279 (PD1) Antibody, anti-human, PE.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Ciancaglini C, et al. (2026) Protocol to isolate, expand, and activate human type 2 innate lymphoid cells to study immune checkpoint function. STAR protocols, 7(2), 104461.

Marsile-Medun S, et al. (2026) Comprehensive analysis of neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy. iScience, 29(4), 115431.

Zheng X, et al. (2025) Protocol for spatial proteomic profiling of tonsil cancer microenvironments using multiplexed imaging-powered deep visual proteomics. STAR protocols, 6(3), 103901.

Miao D, et al. (2025) Photothermal nanofiber-mediated photoporation for gentle and efficient intracellular delivery of macromolecules. Nature protocols, 20(7), 1810.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell reports. Medicine, 6(10), 102400.

Zheng X, et al. (2025) Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics. Molecular cell, 85(5), 1008.

Jeger-Madiot R, et al. (2022) Naive and memory CD4<sup>+</sup> T<sub>H</sub> cell subsets can contribute to the generation of human T<sub>fh</sub> cells. iScience, 25(1), 103566.

Wallstabe L, et al. (2019) ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI insight, 4(18).